RxDoctor Payments Data

Harris Leitstein, NP

Acute Care · Brooklyn, NYNPI 1376772756

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 54 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$817
  • AstraZeneca$164
  • Lilly USA, LLC$56
  • Amgen$50
  • Inspire Medical Systems, Inc.$40
  • Insulet Corporation$34
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$1,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,235 in reported general payments places this provider in the 80th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$8,929
Medicare patients
54
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide659$798,130
JardianceEmpagliflozin523$448,570
OzempicSemaglutide224$253,947
FarxigaDapagliflozin Propanediol148$139,804
JanuviaSitagliptin Phosphate151$118,753
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog273$74,065
JanumetSitagliptin Phos/Metformin Hcl47$46,825
Janumet XrSitagliptin Phos/Metformin Hcl56$44,358
RybelsusSemaglutide43$44,328
MounjaroTirzepatide37$41,677
KerendiaFinerenone44$34,335
Tresiba Flextouch U-200Insulin Degludec33$27,943
Novolog FlexpenInsulin Aspart175$26,468
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$23,275
Tresiba Flextouch U-100Insulin Degludec42$21,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$56$839,807696 claims
Novo NordiskOzempic, Rybelsus$817$298,275267 claims
MerckJanuvia, Janumet, Janumet Xr$20$209,936254 claims
AstraZenecaFarxiga$164$139,804148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 980 acute care providers in New York.

Other acute care in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →